-transparent.png){kind=logo}
The semisynthetic taxoid docetaxel was investigated in a phase II study in non-chemotherapy pretreated patients with metastatic urothelial cell cancer. Thirty patients (median age 61, range 45-72) were treated with docetaxel 100 mg m(-2) administered as a 1-h infusion every 3 weeks. Of 29 evaluable patients, four achieved a complete response and five a partial response, for an overall response rate of 31%. The median duration of response was 6 months (range 4-51+). A total of 104 cycles were administered. The median number of cycles given was three (range 1-9). Toxic effects of docetaxel mainly consisted of neutropenia, which, however, rarely caused infectious complications (5%). Fluid retention or neuropathy necessitated treatment cessation in two patients. We conclude that docetaxel is an effective agent in urothelial cell cancer, and should be further tested in combination chemotherapy.
R de Wit, and
W H Kruit, and
G Stoter, and
M de Boer, and
J Kerger, and
J Verweij
February 2008,
Journal of cancer research and clinical oncology,
R de Wit, and
W H Kruit, and
G Stoter, and
M de Boer, and
J Kerger, and
J Verweij
January 2005,
Oncology,
R de Wit, and
W H Kruit, and
G Stoter, and
M de Boer, and
J Kerger, and
J Verweij
October 1998,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R de Wit, and
W H Kruit, and
G Stoter, and
M de Boer, and
J Kerger, and
J Verweij
December 2006,
Cancer chemotherapy and pharmacology,
R de Wit, and
W H Kruit, and
G Stoter, and
M de Boer, and
J Kerger, and
J Verweij
June 1996,
Medical oncology (Northwood, London, England),
R de Wit, and
W H Kruit, and
G Stoter, and
M de Boer, and
J Kerger, and
J Verweij
March 2003,
Anti-cancer drugs,
R de Wit, and
W H Kruit, and
G Stoter, and
M de Boer, and
J Kerger, and
J Verweij
October 1994,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R de Wit, and
W H Kruit, and
G Stoter, and
M de Boer, and
J Kerger, and
J Verweij
February 2016,
Clinical genitourinary cancer,
R de Wit, and
W H Kruit, and
G Stoter, and
M de Boer, and
J Kerger, and
J Verweij
June 2004,
Annals of oncology : official journal of the European Society for Medical Oncology,
R de Wit, and
W H Kruit, and
G Stoter, and
M de Boer, and
J Kerger, and
J Verweij
April 2014,
Cancer chemotherapy and pharmacology,
